Jae Cheol Lee

ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 11

Top Venues

Thoracic cancer

BMC cancer

JMIR mHealth and uHealth

Cancer research

Asan Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Asan Medical Center Jan 01 2011

South Korea

Professor :: Oncology

Publications

Jiwon Kim, Chang-Min Choi, Wonjun Ji, Jae Cheol Lee
Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial. Thoracic cancer (2023)
Yun Jung Choi, Da-Som Kim, Young Hoon Sung, Dong Ha Kim, Kyungtaek Im, Hyeonjeong Lee, Chae Won Lee, Jeongin Cho, Joongkee Min, Dong-Cheol Woo, Sung-Eun Kim, Sunho Lee, Yun Jeong Kong, Hyung Chul Ryu, Jae-Sun Kim, Rajesh Rengasamy, Wonjun Ji, Chang-Min Choi, Jae Cheol Lee, Jin Kyung Rho
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer. Cancer research (2022)
Ju Hyun Oh, Chang-Min Choi, Seulgi Kim, Woo Sung Kim, Hee Sang Hwang, Se Jin Jang, Sang Young Oh, Mi Young Kim, Jae Cheol Lee, Wonjun Ji
Diagnostic yield and safety of biopsy guided by electromagnetic navigation bronchoscopy for high-risk pulmonary nodules. Thoracic cancer 12 (10) (2021)
Yoon Jung Jang, Dong-Gon Hyun, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji, Jae Cheol Lee
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. BMC cancer 21 (1) (2021)
Cheol-Kyu Park, Sung-Yong Lee, Jae Cheol Lee, Chang-Min Choi, Shin-Yup Lee, Tae-Won Jang, In Jae Oh, Young-Chul Kim
Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A. Thoracic cancer 12 (4) (2020)
Ji Hyun Park, Byoung Soo Kwon, So Jung Park, Wonjun Ji, Shinkyo Yoon, Chang-Min Choi, Jae Cheol Lee
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. Journal of cancer research and clinical oncology 145 (7) (2019)
Wonjun Ji, Hee Kwon, Sungin Lee, Seulgi Kim, Jeong Sook Hong, Yu-Rang Park, Hyeong Ryul Kim, Jae Cheol Lee, Eun Ji Jung, Donghyun Kim, Chang-Min Choi
Mobile Health Management Platform-Based Pulmonary Rehabilitation for Patients With Non-Small Cell Lung Cancer: Prospective Clinical Trial. JMIR mHealth and uHealth 7 (6) (2019)
Sojung Park, Ji Youn Kim, Jae Cheol Lee, Hyeong Ryul Kim, Seungjae Song, Hee Kwon, Wonjun Ji, Chang-Min Choi
Mobile Phone App-Based Pulmonary Rehabilitation for Chemotherapy-Treated Patients With Advanced Lung Cancer: Pilot Study. JMIR mHealth and uHealth 7 (2) (2019)
Dong Kyu Oh, Won Jun Ji, Woo Sung Kim, Chang-Min Choi, Shin-Kyo Yoon, Jin Kyung Rho, Jae Cheol Lee
Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice. PloS one 14 (1) (2019)
Yu-Rang Park, Soo Hyeon Bae, Wonjun Ji, Eul-Ju Seo, Jae Cheol Lee, Hyeong Ryul Kim, Se Jin Jang, Chang-Min Choi
GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers. Journal of Korean medical science 32 (11) (2018)
Sojung Park, Hyun Jung Kim, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Jung-Shin Lee, Woo Sung Kim, Se Hoon Choi, Jin Kyung Rho, Jae Cheol Lee
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. BMC cancer 16 (2016)

Jae Cheol Lee.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jae Cheol Lee